Transthyretin cardiac amyloidosis: an evolving paradigm in recognition, diagnosis, and treatment
- 1Division of Cardiology, Mayo Clinic Arizona , Phoenix, AZ, United States
- 2Division of Cardiology, Department of Medicine, Alpert Medical School of Brown University , Providence, RI, United States
Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) has evolved from an underrecognized and largely untreatable infiltrative cardiomyopathy into a paradigm of precision cardiovascular medicine. The disease arises from transthyretin tetramer destabilization, protein misfolding, and progressive extracellular amyloid deposition, processes that ultimately shape its multisystem clinical phenotype. Importantly, the biology of ATTR-CM is often clinically apparent years before overt heart failure through extracardiac manifestations, including carpal tunnel syndrome, spinal stenosis, and tendon disease,. Recognition of this disease continuum has transformed diagnostic strategies, with contemporary evaluation integrating clinical red flags, multimodality imaging, exclusion of light-chain amyloidosis, radionuclide imaging, and genetic testing to establish ATTR subtype. Emerging artificial intelligence-enabled electrocardiographic and imaging approaches may further shift recognition toward earlier, pre-diagnostic disease recognition, although their clinical utility requires prospective validation. Management has undergone an equally profound transformation. Beyond physiology-guided treatment of heart failure, atrial fibrillation, and thromboembolic risk, disease-modifying therapies now directly target the amyloidogenic cascade through stabilization of circulating transthyretin or suppression of its hepatic synthesis. Cardiovascular outcome evidence for TTR silencers is currently agent-specific: vutrisiran demonstrated clinical benefit in HELIOS-B, whereas eplontersen did not significantly reduce the primary cardiovascular endpoint in CARDIO-TTRansform. The therapeutic frontier is expanding further toward monoclonal antibodies designed to promote clearance of established amyloid deposits, raising the possibility of moving from disease stabilization toward myocardial amyloid regression. This review integrates the molecular pathogenesis, clinical and imaging phenotype, contemporary diagnostic framework, emerging role of artificial intelligence, and rapidly evolving therapeutic landscape of ATTR-CM.
Related
- Delayed Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis Presenting with Autonomic Neuropathy: A Case Report
- Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies
- How to individualize device therapy in transthyretin cardiac amyloidosis: A dyssynchrony-based case report.
- Demographic Representation in Clinical Trials for Transthyretin-Associated Cardiac Amyloidosis: A Systematic Review
- Survival Outcomes in Transthyretin Cardiac Amyloidosis in the Tafamidis Era: Real-World Evidence from Greece
BibTeX
@article{bukhari2026transthyretin,
title = {{Transthyretin cardiac amyloidosis: an evolving paradigm in recognition, diagnosis, and treatment}},
author = {Syed Bukhari and Maisha Maliha and Hesham M. Abdalla and Aya Elalfy and Zoha Majeed and Edward Hulten and Said Alsidawi},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = nov,
doi = {10.3389/fcvm.2026.2009592},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.2009592/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Transthyretin cardiac amyloidosis: an evolving paradigm in recognition, diagnosis, and treatment
AU - Syed Bukhari
AU - Maisha Maliha
AU - Hesham M. Abdalla
AU - Aya Elalfy
AU - Zoha Majeed
AU - Edward Hulten
AU - Said Alsidawi
PY - 2026
DA - 2026/11/09
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.2009592
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.2009592/full
AB - Transthyretin amyloid cardiomyopathy (ATTR-CM) has evolved from an underrecognized and largely untreatable infiltrative cardiomyopathy into a paradigm of precision cardiovascular medicine. The disease arises from transthyretin tetramer destabilization, protein misfolding, and progressive extracellular amyloid deposition, processes that ultimately shape its multisystem clinical phenotype. Importantly, the biology of ATTR-CM is often clinically apparent years before overt heart failure through extracardiac manifestations, including carpal tunnel syndrome, spinal stenosis, and tendon disease,. Recognition of this disease continuum has transformed diagnostic strategies, with contemporary evaluation integrating clinical red flags, multimodality imaging, exclusion of light-chain amyloidosis, radionuclide imaging, and genetic testing to establish ATTR subtype. Emerging artificial intelligence-enabled electrocardiographic and imaging approaches may further shift recognition toward earlier, pre-diagnostic disease recognition, although their clinical utility requires prospective validation. Management has undergone an equally profound transformation. Beyond physiology-guided treatment of heart failure, atrial fibrillation, and thromboembolic risk, disease-modifying therapies now directly target the amyloidogenic cascade through stabilization of circulating transthyretin or suppression of its hepatic synthesis. Cardiovascular outcome evidence for TTR silencers is currently agent-specific: vutrisiran demonstrated clinical benefit in HELIOS-B, whereas eplontersen did not significantly reduce the primary cardiovascular endpoint in CARDIO-TTRansform. The therapeutic frontier is expanding further toward monoclonal antibodies designed to promote clearance of established amyloid deposits, raising the possibility of moving from disease stabilization toward myocardial amyloid regression. This review integrates the molecular pathogenesis, clinical and imaging phenotype, contemporary diagnostic framework, emerging role of artificial intelligence, and rapidly evolving therapeutic landscape of ATTR-CM.
SN - 2297-055X
ER -